COMPOSITIONS FOR METABOLIC HEALTH
Provided herein, inter alia, are compositions comprising one or more biologically pure strains of bacteria as well as methods of making and using the same to treat and/or prevent one or more obesity related disorders in a subject m need thereof.
1 . A composition comprising at least one or more of (a) a biologically pure strain of Eubacterium eligens; (b) a biologically pure strain of Intestinimonas massiliensis; (c) a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of Prevotella copri deposited at the German Collection of Microorganisms and Cell Cultures (DSM) under number DSM 33457; and/or (d) a biologically pure strain of an Akkermansia sp., wherein said Akkermansia sp. is not (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia.
2 . The composition of claim 1 , wherein genome-wide average nucleotide identity (gANI) between said Akkermansia sp. and (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia is less than about 95%.
3 . The composition of claim 1 or claim 2 , comprising (a) a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of E. eligens deposited at DSM under number DSM 33458; and/or (b) a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of I. massiliensis deposited at DSM under number DSM 33460.
4 . The composition of any one of claims 1 - 3 , comprising (a) the E. eligens strain deposited at DSM under number DSM 33458 or a live strain having all of the identifying characteristics of the E. eligens strain deposited at DSM under number DSM 33458; (b) the I. massiliensis strain deposited at DSM under number DSM 33460 or a live strain having all of the identifying characteristics of the I. massiliensis strain deposited at DSM under number DSM 33460; (c) the P. copri strain deposited at DSM under number DSM 33457 or a live strain having all of the identifying characteristics of the P. copri strain deposited at DSM under number DSM 33457; and/or (d) the Akkermansia sp. deposited at DSM wider number DSM 33459 or a live strain having all of the identifying characteristics of the Akkermansia sp. deposited at DSM under number DSM 33459 either (A) alone; and/or (B) in combination with a culture supernatant derived from one or more of these strains.
5 . The composition of claim 1 , comprising (b) a biologically pure strain of Intestinimonas massiliensis; and (d) a biologically pure strain of an Akkermansia sp., wherein said Akkermansia sp. is not (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia.
6 . The composition of claim 5 , comprising (b) a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of I. massiliensis deposited at DSM under number DSM 33460.
7 . The composition of claim 5 or claim 6 , wherein genome-wide average nucleotide identity (gANI) between said Akkermansia sp. and (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia is less than about 95%.
8 . The composition of any one of claims 5 - 7 , comprising (b) the I. massiliensis strain deposited at DSM under number DSM 33460or a live strain having all of the identifying characteristics of the I. massiliensis strain deposited at DSM under number DSM 33460; and
(d) the Akkermansia sp. deposited at DSM under number DSM 33459or a live strain having all of the identifying characteristics of the Akkermansia sp. deposited at DSM under number DSM 33459.
9 . A composition comprising isolated bacterial extracellular vesicles (EVs) derived from at least one or more of (a) a biologically pure strain of Eubacterium eligens; (b) a biologically pure strain of Intestinimonas massiliensis; (c) a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of Prevotella copri deposited at the German Collection of Microorganisms and Cell Cultures (DSM) under number DSM 33457; and/or (d) a biologically pure strain of an Akkermansia sp., wherein said Akkermansia sp. is not (i) Akkermansia muciniphila; or (ii) Akkermansia
10 . The composition of claim 9 , further comprising one or more bacteria from (a), (b), (c), and/or (d).
11 . The composition of claim 9 or claim 10 , wherein genome-wide average nucleotide identity (gANI) between said Akkermansia sp. and (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia is less than about 95%.
12 . The composition of any one of claims 9 - 11 , comprising (a) EVs derived from a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of E. eligens deposited at DSM under number DSM 33458; and/or (b) EVs derived from a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of I. massiliensis deposited at DSM under number DSM 33460.
13 . The composition of any one of claims 9 - 12 , comprising (a) EVs derived from the E. eligens strain deposited at DSM under number DSM 33458 or a live strain having all of the identifying characteristics of the E. eligens strain deposited at DSM under number DSM 33458; (b) EVs derived from the I. massiliensis strain deposited at DSM under number DSM 33460 or a live strain having all of the identifying characteristics of the I. massiliensis strain deposited at DSM under number DSM 33460; (c) EVs derived from the P. copri strain deposited at DSM under number DSM 33457 or a live strain having all of the identifying characteristics of the P. copri strain deposited at DSM under number DSM 33457; and/or (d) EVs derived from the Akkermansia sp. deposited at DSM under number DSM 33459 or a live strain having all of the identifying characteristics of the Akkermansia sp. deposited at DSM under number DSM 33459 either (A) alone; and/or (B) in combination with a culture supernatant derived from one or more of these strains.
14 . The composition of claim 9 or claim 10 , comprising (b) EVs derived from a biologically pure strain of Intestinimonas massiliensis; and (d) EVs derived from a biologically pure strain of an Akkermansia sp., wherein said Akkermansia sp. is not (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia.
15 . The composition of claim 14 , comprising (b) EVs derived from a bacterial strain having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of I. massiliensis deposited at DSM under number DSM 33460.
16 . The composition of claim 14 or claim 15 , wherein genome-wide average nucleotide identity (gANI) between said Akkermansia sp. and (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia is less than about 95%.
17 . The composition of any one of claims 14 - 16 , comprising (b) EVs derived from the I. massiliensis strain deposited at DSM under number DSM 33460or a live strain having all of the identifying characteristics of the I. massiliensis strain deposited at DSM under number DSM 33460; and (d) EVs derived from the Akkermansia sp. deposited at DSM under number DSM 334590r a live strain having all of the identifying characteristics of the Akkermansia sp. deposited at DSM under number DSM 33459. The composition of any one of claims 1 - 16 , wherein the composition is formulated for oral administration.
18 . The composition of any one of claims 1 - 17 , wherein the composition is lyophilized or freeze dried.
19 . The composition of any one of claims 1 - 18 , wherein the composition is encapsulated or coated.
20 . The composition of any one of claims 1 - 19 , wherein the composition is a food product, food ingredient, dietary supplement, or medicament.
21 . The composition of any one of claims 1 - 20 , wherein at least about 1×10 4 CFU/g composition to at least about 1×10 12 CFU/g composition of bacteria is present in the composition.
22 . The composition of any one of claims 1 - 21 , wherein the composition is a probiotic.
23 . The composition of any one of claims 1 - 22 , wherein the composition has been pasteurized or heat treated.
24 . The composition of any one of claims 1 - 23 , wherein the composition is a pharmaceutical composition and further comprises at least one pharmaceutically acceptable carrier and/or excipient.
25 . A tablet, prolonged-release capsule, prolonged-release granule, powder, sachet, or gummy comprising the composition of any one of claims 1 - 24 .
26 . A kit comprising (a)(i) the composition of any one of claims 1 - 24 ; or (ii) the tablet, prolonged-release capsule, prolonged-release granule, powder, sachet, or gummy of claim 25 and b) written instructions for administration to a subject.
27 . A method for treating and/or preventing one or more obesity related disorders in a subject in need thereof, comprising administering a therapeutically effective amount of the composition of any one of claims 1 - 24 or the tablet, prolonged-release capsule, prolonged-release granule, powder, sachet, or gummy of claim 25 to the subject.
28 . The method of claim 27 , wherein the obesity related disorder is one or more disorders selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin deficiency-related disorders, insulin-resistance related disorders, glucose intolerance, abnormal lipid metabolism, non-alcoholic fatty liver disease, hepatic steatosis, leptin resistance, reduced resistin levels, and/or cardiovascular disease.
29 . A method for making a composition comprising combining a biologically pure strain of Intestinimonas massiliensis and a biologically pure strain of an Akkermansia sp., wherein said Akkermansia sp. is not (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia.
30 . A method for making a composition comprising deriving and combining extracellular vesicles (EVs) from a biologically pure strain of Intestinimonas massiliensis and a biologically pure strain of an Akkermansia sp. and wherein said Akkermansia sp. is not (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia.
31 . The method of claim 29 or claim 30 , wherein the genome-wide average nucleotide identity (gANI) between said Akkermansia sp. and (i) Akkermansia muciniphila; or (ii) Akkermansia glycaniphilia is less than about 95%.
32 . The method of any one of claims 29 - 31 , wherein the I. massiliensis comprises a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of I. massiliensis deposited at DSM under number DSM 33460.
33 . The method of any one of claims 29 - 32 , wherein the I. massiliensis comprises the I. massiliensis strain deposited at DSM under number DSM 33460or a live strain having all of the identifying characteristics of the I. massiliensis strain deposited at DSM under number DSM 33460; and wherein the Akkermansia sp. comprises the Akkermansia sp. deposited at DSM under number DSM 33459or a live strain having all of the identifying characteristics of the Akkermansia sp. deposited at DSM under number DSM 33459.
34 . The method of any one of claims 29 - 33 , further comprising freeze frying or lyophilizing the composition.
35 . A composition for use in the prevention and/or treatment of one or more obesity-related disorders in a subject in need thereof, comprising the composition of any one of claims 1 - 24 or the tablet, prolonged-release capsule, prolonged-release granule, powder, sachet, or gummy of claim 25 to the subject.
36 . The composition for use of claim 35 , wherein the obesity related disorder is one or more disorders selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin deficiency-related disorders, insulin-resistance related disorders, glucose intolerance, abnormal lipid metabolism, non-alcoholic fatty liver disease, hepatic steatosis, leptin resistance, reduced resistin levels, and/or cardiovascular disease.